Literature DB >> 15455144

Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.

Martin J I Andrews1, Campbell McInnes, George Kontopidis, Lorraine Innes, Angela Cowan, Andy Plater, Peter M Fischer.   

Abstract

Inhibition of cyclin A- and cyclin E-associated cyclin-dependent kinase-2 (CDK2) activities is an effective way of selective induction of apoptotic cell death via the E2F pathway in tumour cells. The cyclin groove recognition motif (CRM) in the natural CDK-inhibitory (CDKI) tumour suppressor protein p27KIP1 was used as the basis for the design and synthesis of a series of cyclic peptides whose biological activity and structural characterisation by NMR and X-ray crystallography is reported. Whereas linear p27KIP1 sequence peptides were comparatively ineffective, introduction of side chain-to-tail constraints was found to be productive. An optimal macrocyclic ring size for the conformational constraint was determined, mimicking the intramolecular H-bonding system of p27. Molecular dynamics calculations of various macrocycles suggested a close correlation between ring flexibility and biological activity. Truncated inhibitor peptide analogues also confirmed the hypothesis that introduction of a cyclic conformational constraint is favourable in terms of affinity and potency. The structural basis for the potency increase in cyclic versus linear peptides was demonstrated through the determination and interpretation of X-ray crystal structures of complexes between CDK2/cylin A (CDK2A) and a constrained pentapeptide. Copyright 2004 The Royal Society of Chemistry

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15455144     DOI: 10.1039/B409157D

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  13 in total

1.  A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.

Authors:  Patrick Corsino; Nicole Horenstein; David Ostrov; Thomas Rowe; Mary Law; Amanda Barrett; George Aslanidi; W Douglas Cress; Brian Law
Journal:  J Biol Chem       Date:  2009-08-26       Impact factor: 5.157

Review 2.  Targeting kinase signaling pathways with constrained peptide scaffolds.

Authors:  Laura E Hanold; Melody D Fulton; Eileen J Kennedy
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

3.  Targeting the cyclin-binding groove site to inhibit the catalytic activity of CDK2/cyclin A complex using p27(KIP1)-derived peptidomimetic inhibitors.

Authors:  Arumugasamy Karthiga; Sunil Kumar Tripathi; Ramasamy Shanmugam; Venkatesan Suryanarayanan; Sanjeev Kumar Singh
Journal:  J Chem Biol       Date:  2014-09-18

4.  Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements.

Authors:  Shu Liu; Joshua K Bolger; Lindsay O Kirkland; Padmavathy N Premnath; Campbell McInnes
Journal:  ACS Chem Biol       Date:  2010-10-14       Impact factor: 5.100

5.  Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.

Authors:  Mary E Law; Patrick E Corsino; Satya Narayan; Brian K Law
Journal:  Mol Pharmacol       Date:  2015-05-27       Impact factor: 4.436

6.  Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors.

Authors:  Padmavathy Nandha Premnath; Shu Liu; Tracy Perkins; Jennifer Abbott; Erin Anderson; Campbell McInnes
Journal:  Bioorg Med Chem       Date:  2013-11-07       Impact factor: 3.641

Review 7.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

8.  Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly.

Authors:  Shu Liu; Padmavathy Nandha Premnath; Joshua K Bolger; Tracy L Perkins; Lindsay O Kirkland; George Kontopidis; Campbell McInnes
Journal:  J Med Chem       Date:  2013-02-12       Impact factor: 7.446

9.  Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.

Authors:  Giulio Rastelli; Andrew Anighoro; Martina Chripkova; Laura Carrassa; Massimo Broggini
Journal:  Cell Cycle       Date:  2014-06-09       Impact factor: 4.534

10.  Identification of Novel Cyclin A2 Binding Site and Nanomolar Inhibitors of Cyclin A2-CDK2 Complex.

Authors:  Stephanie S Kim; Michele J Alves; Patrick Gygli; Jose Otero; Steffen Lindert
Journal:  Curr Comput Aided Drug Des       Date:  2021       Impact factor: 1.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.